Research News and Research

RSS

Adolescent drinking: Laws tighten

Latest study findings show that adolescents offered alcohol by someone other than their parents are six times more likely to drink to excess. The research comes from Deakin University and has made the Australian Drug Foundation tighten laws across Australia, making it illegal to give children alcohol without their parents' permission.

7 Nov 2010

Fast food restaurants to display calorie counts

As Australia reels under the weight of obesity and related diseases one of the first steps towards prevention could be forcing fast food restaurants to display kilojoule counts on their menus said NSW Premier Kristina Keneally.

7 Nov 2010

Mass. focuses on containing health care costs, Gov. Schwarzenegger seeks to expand coverage of uninsured in Calif.

While the White House seems destined to spend the next two years fending off attacks on President Obama's health care law, the administration of Governor Deval Patrick of Massachusetts will push forward with the next stage of health care overhaul: trying to contain the escalating costs of medical care.

7 Nov 2010

Al Jazeera examines international trade agreement negotiations, access to generic medicines in low-income countries

Al Jazeera examines what the outcomes of two international trade agreement negotiations - one regarding free trade between the EU and India and the other over anti-counterfeiting measures - could mean for patients living with HIV/AIDS in low-income countries.

7 Nov 2010

Scientists discover new way to create human blood from adult skin

In an important breakthrough, scientists at McMaster University have discovered how to make human blood from adult human skin. The discovery, published in the prestigious science journal Nature today, could mean that in the foreseeable future people needing blood for surgery, cancer treatment or treatment of other blood conditions like anemia will be able to have blood created from a patch of their own skin to provide transfusions.

7 Nov 2010

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.

7 Nov 2010

KHN column: Health care cost control is hard, and humbling

Though lots of different approaches to controlling health care costs have been discussed, it's hard to know which of them will really work.

7 Nov 2010

Melanoma drug breakthrough

Two latest drugs useful in melanoma are termed as the biggest breakthrough in the last five decades say cancer experts. These drugs are the first ones to be effective in advanced forms of the cancer.

5 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

First Edition: November 4, 2010

Less than 24 hours after Republicans won control of the House, soon-to-be-speaker John Boehner denounced the new health care law, saying it would "kill jobs in America, ruin the best health care system in the world, and bankrupt our country" -- and renewed his vow to try to repeal it. Kaiser Health News asked people around the country to answer the following question: "If you ended up in an elevator with Rep. Boehner, what single thing would you urge him to do about health care in this country? (Kaiser Health News).

4 Nov 2010

CaPre drug candidate effective in managing impaired glucose tolerance

Neptune Technologies & Bioressources Inc. subsidiary Acasti Pharma Inc. reports preclinical results showing that its leading drug candidate CaPre, performed significantly better than the currently marketed drug, Lovaza, at managing impaired glucose tolerance (IGT) a serious pre-diabetic state associated with increased risk of diabetes and heart disease.

4 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

Valeant third quarter revenue decreases 2% to $208.3 million

Valeant Pharmaceuticals International, Inc. announces third quarter financial results for 2010. The merger of Biovail Corporation and Valeant Pharmaceuticals International was completed on September 28, 2010.

4 Nov 2010

Undamaged portions of brain 'take over' and support recovery of function: Study

New research provides fascinating insight into mechanisms that underlie recovery after damage to a region of the brain important for memory and attention. The research, published by Cell Press in the November 4th issue of the journal Neuron, highlights the role of undamaged portions of the brain that can "take over" and support the recovery of function.

4 Nov 2010

Viking Systems third quarter sales decreases 8% to $1,832,502

Viking Systems, Inc. today announced financial results for its third quarter ended September 30, 2010. The Company reported a net loss for the quarter ended September 30, 2010 of $632,565 or $0.01 per share and net loss of $1,378,865 or $0.03 per share for the nine months ended September 30, 2010.

4 Nov 2010

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.

4 Nov 2010

CombiMatrix receives $488,958 grant under QTDP program

CombiMatrix Corporation a molecular diagnostics company with a focus on DNA-based clinical diagnostic testing services for oncology and pre-and postnatal developmental disorders, announced today the award of $488,958 under the Internal Revenue Service's Section 48D for Qualifying Therapeutic Discovery Projects.

4 Nov 2010

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

4 Nov 2010

Antigenics awarded $424,720 grant under QTDP program

Antigenics Inc. today announced that it has been awarded $424,720 in grants under the IRS' Qualifying Therapeutic Discovery Project (QTDP) program. The grants were awarded in recognition of our two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon® adjuvant.

4 Nov 2010

Inspire third quarter net loss decreases to $7.6 million

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2010, reporting a net loss of $7.6 million or ($0.09) per share, an improvement from the third quarter of 2009 during which the Company incurred a net loss of $8.5 million or ($0.12) per share.

4 Nov 2010